InMed Pharmaceuticals Inc (INM)

[PharmaGreen007]

UBC helped develop a drug that saved the vision of approximately 500,000 people:

This is where Dr. Yadav will help develop up to 6 therapies (including glaucoma and arthritis) and delivery systems (drops,gels and patches) for InMed:

Check out the photo Gallery where all of our world renowned scientists will be working:

(click gallery)
http://henriquezpartners.com/work/michael-smith-lab/

UBC Milestones:

2004
Opening of Michael Smith Laboratories, a $30-million biotechnology research facility, housing UBC's Biotechnology Laboratory and named after the Nobel Laureate, who passed away in 2000.

1993
UBC biochemist Michael Smith wins the Nobel Prize for developing the technique of site-directed mutagenesis, which allows the DNA sequence of any gene to be altered in a designated manner. He donates the prize money to researchers working on the genetics of schizophrenia, to Science World BC, and to the Society for Canadian Women in Science and Technology.

1994
Canadian scientist and UBC alumnus Bertram Brockhouse shares the 1994 Nobel Prize in Physics with American Clifford Shull for developing neutron scattering techniques for studying condensed matter.

2000
UBC spin-off company QLT begins sales of Visudyne, the world's first treatment for age-related macular degeneration, the most common cause of blindness. Based on the work of UBC chemistry professor David Dolphin and immunologist and alumna Julia Levy, the drug has saved the vision of approximately 500,000 people, and QLT has gone to become UBC's most successful spin-off.<<<

http://science.ubc.ca/about/history

All about Dr. Yadav:


Dr. Yadav

"The development process is focussing on a nanoparticle-based delivery system for our current and future therapies. The delivery system is currently under investigation in in vitro and in vivo animal models. The highly lipophilic nature of cannabinoids demands the development of an innovative and efficient delivery system.

Chief Scientific Officer, Dr. Sazzad Hossain states, "We believe the development of this delivery system will position InMed to increase efficacies of our therapies as well as open additional industry opportunities for licensing and collaboration in other disease areas. We are fortunate to have created this alliance with Dr. Yadav, the principal investigator of this project."

Dr. Yadav
Assistant Professor of Chemical & Biological Engineering, The University of British Columbia
Vancouver, British Columbia, CanadaBiotechnology
Current
Department of Chemical & Biological Engineering, The University of British Columbia
Previous
Department of Chemistry & Chemical Biology, Harvard University, Department of Chemical Engineering, Massachusetts Institute of Technology, Harvard-MIT Division of Health Sciences & Technology
Education
Harvard University

https://ca.linkedin.com/in/vgyadav